Therapeutics

AGB101

Overview

Name: AGB101
Synonyms: levetiracetam
Chemical Name: (S)-α-Ethyl-2-oxo-1-pyrrolidineacetamide
Therapy Type: Small Molecule (timeline)
Target Type: Amyloid-Related (timeline)
Condition(s): MCI-AD
U.S. FDA Status: MCI-AD (Phase 3)
Company: AgeneBio, Inc.

Background

AGB101 is a proprietary, once-daily, extended-release, low-dose formulation of the FDA-approved atypical anti-convulsant medication levetiracetam. AGB101 corresponds to roughly 1/12 of the dose typically prescribed for epilepsy, according to AGeneBio.

Findings

In September 2015, AGeneBio received a $7.5 million grant from the National Institutes on Aging toward evaluating AGB101, and announced that it intended to begin a Phase 3 trial of this formulation in 2016 (company press release). Further NIA funds were received in September 2017, a trial start announced for 2018 (press release), and the first patient enrolled in January 2019 (press release).

Conducted at 23 sites in the United States and Canada, the trial will evaluate AGB101 safety, and its efficacy at slowing cognitive and functional impairment in 830 people who fulfill criteria for MCI and have a positive PET scan for brain amyloid. Participants will receive 220 mg AGB101 or placebo once daily for 78 weeks. The primary outcome is change in CDR-SB score at 78 weeks; secondary measures include change on the MMSE and Functional Activities Questionnaire. An imaging substudy will include structural MRI and tau PET imaging with MK-6240 in 160 participants at baseline and after treatment (outside news coverage). The trial will run through November 2022.

In April 2019, a Phase 2 research study on AGB101 began at Medical College of Wisconsin. This crossover trial compares the effects of 2 weeks of 220 mg/day AGB101 or placebo on functional brain networks. It will enroll 50 healthy older people, half ApoE4 carriers and half noncarriers. The primary endpoint will be change in functional connectivity in the hippocampus and default mode networks, assessed by functional MRI; secondary measures include tests of episodic memory.

Last Updated: 18 Oct 2019

Comments

No Available Comments

Make a Comment

To make a comment you must login or register.

References

Therapeutics Citations

  1. Levetiracetam

External Citations

  1. company press release
  2. press release
  3. press release
  4. outside news coverage

Further Reading

Papers

  1. . Response of the medial temporal lobe network in amnestic mild cognitive impairment to therapeutic intervention assessed by fMRI and memory task performance. Neuroimage Clin. 2015;7:688-98. Epub 2015 Feb 21 PubMed.
  2. . Levetiracetam Alters Oscillatory Connectivity in Alzheimer's Disease. J Alzheimers Dis. 2017;58(4):1065-1076. PubMed.
  3. . Neurobehavioral characterization of APP23 transgenic mice with the SHIRPA primary screen. Behav Brain Res. 2005 Feb 10;157(1):91-8. PubMed.
  4. . Amyloid beta-induced neuronal hyperexcitability triggers progressive epilepsy. J Neurosci. 2009 Mar 18;29(11):3453-62. PubMed.
  5. . Antiepileptics Topiramate and Levetiracetam Alleviate Behavioral Deficits and Reduce Neuropathology in APPswe/PS1dE9 Transgenic Mice. CNS Neurosci Ther. 2013 Nov;19(11):871-81. PubMed.
  6. . Treatment strategies targeting excess hippocampal activity benefit aged rats with cognitive impairment. Neuropsychopharmacology. 2010 Mar;35(4):1016-25. PubMed.
  7. . Incidence and impact of subclinical epileptiform activity in Alzheimer's disease. Ann Neurol. 2016 Dec;80(6):858-870. Epub 2016 Nov 7 PubMed.